Cargando…

Myelo-Enhancement by Astragalus Membranaceus in Male Albino Rats with Chemotherapy Myelo-Suppression. Histological and Immunohistochemical Study

BACKGROUND AND OBJECTIVES: Myelosuppression is the most common toxicity encountered in the oncology clinic today. This study was planned to investigate the possible protective and therapeutic role of the traditional Chinese Medicinal Herb; Astragalus Membranaceus (AM), on chemotherapy-induced myelos...

Descripción completa

Detalles Bibliográficos
Autores principales: Ismail, Zeinab Mohamed Kamel, Amin, Noha Mohamed Afifi, Yacoub, Mira Farouk Youssef, Mohamed, Amira Mohamed Osman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Stem Cell Research 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049727/
https://www.ncbi.nlm.nih.gov/pubmed/24921023
http://dx.doi.org/10.15283/ijsc.2014.7.1.12
_version_ 1782319859393101824
author Ismail, Zeinab Mohamed Kamel
Amin, Noha Mohamed Afifi
Yacoub, Mira Farouk Youssef
Mohamed, Amira Mohamed Osman
author_facet Ismail, Zeinab Mohamed Kamel
Amin, Noha Mohamed Afifi
Yacoub, Mira Farouk Youssef
Mohamed, Amira Mohamed Osman
author_sort Ismail, Zeinab Mohamed Kamel
collection PubMed
description BACKGROUND AND OBJECTIVES: Myelosuppression is the most common toxicity encountered in the oncology clinic today. This study was planned to investigate the possible protective and therapeutic role of the traditional Chinese Medicinal Herb; Astragalus Membranaceus (AM), on chemotherapy-induced myelosuppression. METHODS AND RESULTS: This study was carried out on thirty six adult male albino rats. They were divided into: Group I Control Group (n=6) received a vehicle of phosphate buffered saline (PBS) solution. Group II (n=12) were injected I.P. with cyclophosphamide (CY) for 3 days (gIIa n =6) and continued for one more week to receive AM orally (gIIb n=6). Group III (n=6) received CY I.P. together with AM orally for 3 days. Group IV (n=12) received AM orally for one week (gIVa n=6) and continued for extra three days receiving CY I.P. with AM orally (gIVb n=6). Blood samples were analysed for Total Leucocytic Count and Lymphocytic Count. Counting of CD34 +ve cells in bone marrow was performed by flowcytometry. Bone marrow sections were subjected to H&E stain as well as immunohistochemical staining for anti- CD20 antibody. The mean area % of cellular bone marrow regions occupied by developing haemopoietic cells, mean area of fat cells and mean number of CD20 immunopositive B lymphocytes in the bone marrow were measured by histomorphometric studies and statistically compared. AM proved to have a myelo-protective and myelo-therapeutic capacity, evidenced at both laboratory and morphological levels. CONCLUSIONS: The greatest myelo-potentiating effect of AM was achieved when supplied before and together with CY therapy.
format Online
Article
Text
id pubmed-4049727
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Korean Society for Stem Cell Research
record_format MEDLINE/PubMed
spelling pubmed-40497272014-06-11 Myelo-Enhancement by Astragalus Membranaceus in Male Albino Rats with Chemotherapy Myelo-Suppression. Histological and Immunohistochemical Study Ismail, Zeinab Mohamed Kamel Amin, Noha Mohamed Afifi Yacoub, Mira Farouk Youssef Mohamed, Amira Mohamed Osman Int J Stem Cells Original Article BACKGROUND AND OBJECTIVES: Myelosuppression is the most common toxicity encountered in the oncology clinic today. This study was planned to investigate the possible protective and therapeutic role of the traditional Chinese Medicinal Herb; Astragalus Membranaceus (AM), on chemotherapy-induced myelosuppression. METHODS AND RESULTS: This study was carried out on thirty six adult male albino rats. They were divided into: Group I Control Group (n=6) received a vehicle of phosphate buffered saline (PBS) solution. Group II (n=12) were injected I.P. with cyclophosphamide (CY) for 3 days (gIIa n =6) and continued for one more week to receive AM orally (gIIb n=6). Group III (n=6) received CY I.P. together with AM orally for 3 days. Group IV (n=12) received AM orally for one week (gIVa n=6) and continued for extra three days receiving CY I.P. with AM orally (gIVb n=6). Blood samples were analysed for Total Leucocytic Count and Lymphocytic Count. Counting of CD34 +ve cells in bone marrow was performed by flowcytometry. Bone marrow sections were subjected to H&E stain as well as immunohistochemical staining for anti- CD20 antibody. The mean area % of cellular bone marrow regions occupied by developing haemopoietic cells, mean area of fat cells and mean number of CD20 immunopositive B lymphocytes in the bone marrow were measured by histomorphometric studies and statistically compared. AM proved to have a myelo-protective and myelo-therapeutic capacity, evidenced at both laboratory and morphological levels. CONCLUSIONS: The greatest myelo-potentiating effect of AM was achieved when supplied before and together with CY therapy. Korean Society for Stem Cell Research 2014-05 /pmc/articles/PMC4049727/ /pubmed/24921023 http://dx.doi.org/10.15283/ijsc.2014.7.1.12 Text en Copyright ©2014, Korean Society for Stem Cell Research This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Ismail, Zeinab Mohamed Kamel
Amin, Noha Mohamed Afifi
Yacoub, Mira Farouk Youssef
Mohamed, Amira Mohamed Osman
Myelo-Enhancement by Astragalus Membranaceus in Male Albino Rats with Chemotherapy Myelo-Suppression. Histological and Immunohistochemical Study
title Myelo-Enhancement by Astragalus Membranaceus in Male Albino Rats with Chemotherapy Myelo-Suppression. Histological and Immunohistochemical Study
title_full Myelo-Enhancement by Astragalus Membranaceus in Male Albino Rats with Chemotherapy Myelo-Suppression. Histological and Immunohistochemical Study
title_fullStr Myelo-Enhancement by Astragalus Membranaceus in Male Albino Rats with Chemotherapy Myelo-Suppression. Histological and Immunohistochemical Study
title_full_unstemmed Myelo-Enhancement by Astragalus Membranaceus in Male Albino Rats with Chemotherapy Myelo-Suppression. Histological and Immunohistochemical Study
title_short Myelo-Enhancement by Astragalus Membranaceus in Male Albino Rats with Chemotherapy Myelo-Suppression. Histological and Immunohistochemical Study
title_sort myelo-enhancement by astragalus membranaceus in male albino rats with chemotherapy myelo-suppression. histological and immunohistochemical study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049727/
https://www.ncbi.nlm.nih.gov/pubmed/24921023
http://dx.doi.org/10.15283/ijsc.2014.7.1.12
work_keys_str_mv AT ismailzeinabmohamedkamel myeloenhancementbyastragalusmembranaceusinmalealbinoratswithchemotherapymyelosuppressionhistologicalandimmunohistochemicalstudy
AT aminnohamohamedafifi myeloenhancementbyastragalusmembranaceusinmalealbinoratswithchemotherapymyelosuppressionhistologicalandimmunohistochemicalstudy
AT yacoubmirafaroukyoussef myeloenhancementbyastragalusmembranaceusinmalealbinoratswithchemotherapymyelosuppressionhistologicalandimmunohistochemicalstudy
AT mohamedamiramohamedosman myeloenhancementbyastragalusmembranaceusinmalealbinoratswithchemotherapymyelosuppressionhistologicalandimmunohistochemicalstudy